NABUMETONE

Post-LOE

nabumetone

Gen Pharmaceuticals

ANDAORALTABLET

Approved

Jan 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

NABUMETONE (nabumetone) by Gen Pharmaceuticals is cyclooxygenase inhibitors [moa]. First approved in 2025.

Drug data last refreshed 23h ago

$0.0BPart D

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT01164813Phase 1Completed

Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fasting Conditions

Started Mar 2006

44 enrolled

Healthy

NCT01164826Phase 1Completed

Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions

Started Mar 2006

30 enrolled

Healthy

Company

Worked on NABUMETONE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.